Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
INTRODUCTION. The Model for End-Stage Liver Desease scale is used to determine the stage of liver disease and for organ allocation in transplant candidates. OBJECTIVE. To validate the usefulness of the scale in adult patients of the Liver Transplantation Program and its application in the prioritization of grafts for patients on the waiting list. MATERIALS AND METHODS. Observational, descriptive study. From a population of 103 Medical Records, a sample of 95 records was taken from the Liver Transplantation Program of the Carlos Andrade Marín Specialty Hospital in the period may 2016 to march 2020. Inclusion criteria: data from patients with a diagnosis of terminal liver disease, of both sexes, aged between 14 and 65 years. The information was taken from the AS400 system and analyzed using the International Business Machines Statistical Package for the Social Sciences, version 23.0 and the Kaplan-Meier estimator. RESULTS. Survival on the waiting list was 86,3% (82; 95) and post-transplant survival was 72,5% (44; 62) at 12 months and 68,9% (42; 62) at 46 months of follow up. DISCUSSION. This scale was considered for seriously ill patients, assigning them a score that allowed them to have the option of receiving a transplant in relation to other patients. CONCLUSIONS. The utility of the scale was validated, no significant difference was found, but it maintained the principle of priority for patients with greater severity.
Meirelles Júnior RF, Salvalaggio P, Rezende MB de, Evangelista AS, Guardia BD, Matielo CEL, et al. Liver transplantation: history, outcomes and perspectives. Einstein São Paulo. marzo de 2015;13(1):149-52. DOI: 10.1590/S1679-45082015RW3164. Available from: https://pubmed.ncbi.nlm.nih.gov/25993082/
Bohórquez HE, Beltrán Gálvis OA. Modelos de pronóstico en enfermedad hepática. Child & Meld. Rev Colomb Gastroenterol. junio de 2004;19(2):109-14. Print version ISSN: 0120-9957. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-99572004000200008
Boerr E, Anders M, Mella J, Quiñonez E, Goldaracena N, Orozco F, et al. Análisis del coste del trasplante hepático en un hospital de la comunidad: su relación con el Model for End-stage Liver Disease, un índice pronóstico que prioriza al paciente más grave. Gastroenterol Hepatol. 1 de enero de 2013;36(1):1-6. DOI: 10.1016/j.gastrohep.2012.08.003. Disponible en: https://www.elsevier.es/es-revista-gastroenterologia-hepatologia-14-articulo-analisis-del-coste-del-trasplante-S0210570512002610
Vargas V, Ortiz M. [Prognostic models of liver cirrhosis. The Model of End-Stage Liver Disease (MELD)]. Gastroenterol Hepatol. abril de 2003;26(4):257-9. DOI: 10.1016/s0210-5705(03)70350-1. Available from: https://pubmed.ncbi.nlm.nih.gov/12681120/
Lladó L, Bustamante J. IV Consensus Meeting of the Spanish Society of Liver Transplantation 2012. Exceptions to model for end-stage liver disease in prioritizing liver transplantation. Gastroenterol Hepatol. febrero de 2014;37(2):83-91. DOI: 10.1016/j.gastrohep.2013.06.011. Available from: https://pubmed.ncbi.nlm.nih.gov/24290253/
Ronald J, Wang Q, Choi SS, Suhocki PV, Hall MD, Smith TP, et al. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation. Diagn Interv Imaging. marzo de 2018;99(3):163-8. DOI: 10.1016/j.diii.2017.10.008. Available from: https://pubmed.ncbi.nlm.nih.gov/29154015/
Cai Q, Zhu M, Duan J, Wang H, Sheng J. Establishment of prognostic scoring models for different etiologies of acute decompensation in hospitalized patients with cirrhosis. J Int Med Res. septiembre de 2019;47(9):4492-504. DOI: 10.1177/0300060519862065. Available from: https://pubmed.ncbi.nlm.nih.gov/31364441/
Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. enero de 2003;124(1):91-6. DOI: 10.1053/gast.2003.50016. Available from: https://pubmed.ncbi.nlm.nih.gov/12512033/
Freeman F, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the First Year of the New Liver Allocation Plan [Internet]. 2004 Jan; 10 (1) 7-15. [citado 20 de mayo de 2020]. DOI: 10.1002/lt.20024. Available from: https://pubmed.ncbi.nlm.nih.gov/14755772/
Colmenero J, Castro-Narro G, Navasa M. Utilidad del MELD (Model for End-stage Liver Disease) para asignar prioridades en el trasplante hepático. Gastroenterol Hepatol. 1 de abril de 2010;33(4):330-6. Disponible en: DOI: 10.1016/j.gastrohep.2009.04.007. Available from: https://www.elsevier.es/es-revista-gastroenterologia-hepatologia-14-articulo-utilidad-del-meld-model-for-S0210570509004300
Pozo-Laderas JC, Rodríguez-Perálvarez M, Muñoz-Villanueva MC, Rivera-Espinar F, Durban-García I, Muñoz-Trujillo J, et al. Predictores pretrasplante de mortalidad precoz en receptores adultos de trasplante hepático en la era MELD-Na. Med Intensiva. 1 de junio de 2019;43(5):261-9. DOI: 10.1016/j.medin.2018.03.008. Disponible en: https://www.medintensiva.org/es-predictores-pretrasplante-mortalidad-precoz-receptores-articulo-S0210569118301219.
De Freitas ACT, Rampim AT, Nunes CP, Coelho JCU. Impact of meld sodium on liver transplantation waiting list. Arq Bras Cir Dig ABCD [Internet]. [citado 12 de junio de 2020];2019; 32(3): e1460. DOI: 10.1590/0102-672020190001e1460. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902892/
Texeira de Freitas A, Shiguihara RS, Monteiro RT, Pazeto TL, Coelho JCU. Compartive study on comparative study oon liver transplantation with and without Hepatocellular carcinoma with cirrhosis: Analysis of Meld, waiting time and survival. Arq Bras Cir Dig ABCD. 2016;29(1):21-5. ISSN 2317-6226. Available from: http://decs.bvs.br/
Dashti H, Ebrahimi A, Khorasani NR, Moazzami B, Khojasteh F, Shabanan SH, et al. The utility of early post-liver transplantation model for end-stage liver disease score in prediction of long-term mortality. Ann Gastroenterol. 2019;32(6):633-41. DOI: 10.20524/aog.2019.0420. Available from: https://pubmed.ncbi.nlm.nih.gov/31700242/
Nafea MA, Alsebaey A, Abd El Aal Sultan A, Goda MH, Salman A, Rashed HS, et al. Predictors of early recipient mortality after living donor liver transplantation in a tertiary care center in Egypt. Ann Saudi Med. octubre de 2019;39(5):337-44. DOI: 10.5144/0256-4947.2019.337. Available from: https://pubmed.ncbi.nlm.nih.gov/31580715/
Huertas J, Garrido D, Serpa F. Organ Transplantation in Ecuador. Transplantation. marzo de 2020;104(3):445–447. DOI: 10.1097/TP.0000000000002974. Available from: https://pubmed.ncbi.nlm.nih.gov/32106198/
Campos-Varela I, Castells L. Puntuaciones de pronóstico de la cirrosis. Gastroenterol Hepatol. 1 de julio de 2008;31(7):439-46. DOI: 10.1157/13125591. Disponible en: https://www.elsevier.es/es-revista-gastroenterologia-hepatologia-14-articulo-puntuaciones-pronostico-cirrosis-S0210570508756486
Kartoun U, Corey KE, Simon TG, Zheng H, Aggarwal R, Ng K, et al. The MELD-Plus: A generalizable prediction risk score in cirrhosis. PloS One. 2017;12(10):e0186301. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186301
Schlegel A, Linecker M, Kron P, Györi G, De Oliveira ML, Müllhaupt B, et al. Risk Assessment in High- and Low-MELD Liver Transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2017;17(4):1050-63. DOI: 10.1111/ajt.14065 . Available from: https://pubmed.ncbi.nlm.nih.gov/27676319/
van Vugt JLA, Alferink LJM, Buettner S, Gaspersz MP, Bot D, Darwish Murad S, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort. J Hepatol. 2018;68(4):707-14. DOI: 10.1016/j.jhep.2017.11.030. Available from: https://pubmed.ncbi.nlm.nih.gov/29221886/
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.
